Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

06/05/15	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
29/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
22/04/15	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
21/04/15	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
09/04/15	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
06/03/15	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
06/03/15	Wall Street closes up slightly ahead of jobs report	RE
05/03/15	AbbVie : CEO says new form of Humira could thwart generics	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/03/15	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/03/15	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
02/06/14	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

08/01/16	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
08/01/16	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
08/01/16	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
08/01/16	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

06/03/15	Wall Street se reprend un peu dans un climat d'attente
06/03/15	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
05/03/15	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	Début d'année en fanfare pour les fusions dans la pharmacie
05/03/15	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	01/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.78%	-1.42%	+2.96%	+21.65%	50.47B
REVOLUTION MEDICINES, INC.	-6.00%	-0.75%	+447.48%	+535.14%	44.56B
IQVIA HOLDINGS INC.	-0.24%	+0.74%	+37.18%	+16.26%	43.08B
BEONE MEDICINES AG	-1.55%	-2.07%	+19.83%	+71.70%	41.7B
CELLTRION, INC.	-0.31%	-0.83%	+19.47%	+48.24%	33.21B
MEDPACE HOLDINGS, INC.	-1.79%	-3.24%	+26.32%	+125.06%	16.77B
ASCENDIS PHARMA A/S	-0.58%	-2.12%	-	-	16.28B
EUROFINS SCIENTIFIC SE	-0.88%	-0.66%	+11.63%	+27.62%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	-1.25%	+78.49%	+42.97%	13.92B
Average	-1.53%	-1.06%	+80.42%	+111.08%	30.51B
Weighted average by Cap.	-1.70%	-1.06%	+96.28%	+129.03%